Follow
Aarron Willingham
Aarron Willingham
Executive Director, Merck Research Laboratories
Verified email at merck.com - Homepage
Title
Cited by
Cited by
Year
RNA maps reveal new RNA classes and a possible function for pervasive transcription
P Kapranov, J Cheng, S Dike, DA Nix, R Duttagupta, AT Willingham, ...
Science 316 (5830), 1484-1488, 2007
29042007
The developmental transcriptome of Drosophila melanogaster
BR Graveley, AN Brooks, JW Carlson, MO Duff, JM Landolin, L Yang, ...
Nature 471 (7339), 473-479, 2011
16672011
Identification of Functional Elements and Regulatory Circuits by Drosophila modENCODE
modENCODE Consortium, S Roy, J Ernst, PV Kharchenko, P Kheradpour, ...
Science 330 (6012), 1787-1797, 2010
10702010
A strategy for probing the function of noncoding RNAs finds a repressor of NFAT
AT Willingham, AP Orth, S Batalov, EC Peters, BG Wen, P Aza-Blanc, ...
Science 309 (5740), 1570-1573, 2005
8562005
Genome-wide transcription and the implications for genomic organization
P Kapranov, AT Willingham, TR Gingeras
Nature Reviews Genetics 8 (6), 413-423, 2007
8522007
A Drosophila mechanosensory transduction channel
RG Walker, AT Willingham, CS Zuker
Science 287 (5461), 2229-2234, 2000
8282000
The transcriptional diversity of 25 Drosophila cell lines
L Cherbas, A Willingham, D Zhang, L Yang, Y Zou, BD Eads, JW Carlson, ...
Genome research 21 (2), 301-314, 2011
2842011
TUF love for “junk” DNA
AT Willingham, TR Gingeras
Cell 125 (7), 1215-1220, 2006
2072006
Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA
H Peacock, RV Fucini, P Jayalath, JM Ibarra-Soza, HJ Haringsma, ...
Journal of the American Chemical Society 133 (24), 9200-9203, 2011
1162011
siRNA-optimized modifications for enhanced in vivo activity
DM Kenski, G Butora, AT Willingham, AJ Cooper, W Fu, N Qi, F Soriano, ...
Molecular Therapy-Nucleic Acids 1, 2012
962012
RNAi and HTS: exploring cancer by systematic loss-of-function
AT Willingham, QL Deveraux, GM Hampton, P Aza-Blanc
Oncogene 23 (51), 8392-8400, 2004
912004
Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo
DM Kenski, AJ Cooper, JJ Li, AT Willingham, HJ Haringsma, TA Young, ...
Nucleic acids research 38 (2), 660-671, 2010
862010
mRNA knockdown by single strand RNA is improved by chemical modifications
HJ Haringsma, JJ Li, F Soriano, DM Kenski, WM Flanagan, AT Willingham
Nucleic acids research 40 (9), 4125-4136, 2012
582012
Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of T regulatory cells
S Sukumar, DC Wilson, Y Yu, J Wong, S Naravula, G Ermakov, R Riener, ...
Cancer Research 77 (16), 4378-4388, 2017
572017
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
M Cancilla, JJ Cunningham, MW Flanagan, HJ Haringsma, D Kenski, ...
US Patent 9,260,471, 2016
572016
Single-stranded microRNA mimics
G Chorn, M Klein-McDowell, L Zhao, MA Saunders, WM Flanagan, ...
Rna 18 (10), 1796-1804, 2012
562012
A tissue specific cytochrome P450 required for the structure and function of Drosophila sensory organs
AT Willingham, T Keil
Mechanisms of development 121 (10), 1289-1297, 2004
552004
Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction
B Bhagwat, H Cherwinski, M Sathe, W Seghezzi, TK McClanahan, ...
Journal of immunological methods 456, 7-14, 2018
362018
Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
L Lim, G Chorn, A Willingham, L Zhao
36*2012
Adenosine modification may be preferred for reducing siRNA immune stimulation
RV Fucini, HJ Haringsma, P Deng, WM Flanagan, AT Willingham
Nucleic acid therapeutics 22 (3), 205-210, 2012
262012
The system can't perform the operation now. Try again later.
Articles 1–20